Baricitinib Offers Promise of Remission in Refractory RA Baricitinib Offers Promise of Remission in Refractory RA

The oral Janus kinase 1 and 2 inhibitor baricitinib significantly increased ACR20 response rates and improved physical function in patients with rheumatoid arthritis for whom other therapies had failed. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Source Type: news